Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00641147
Other study ID # NCI-2013-00536
Secondary ID NCI-2013-00536CD
Status Completed
Phase Phase 2
First received March 17, 2008
Last updated September 27, 2017
Start date October 2010
Est. completion date November 30, 2016

Study information

Verified date September 2017
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized phase II trial studies curcumin in treating patients with familial adenomatous polyposis. Curcumin may prevent colorectal cancer in patients with a history of rectal polyps or colorectal neoplasia.


Description:

Specific Aims:

I. To determine in a randomized, double-blinded, placebo-controlled study the tolerability and effectiveness of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number, and polyp size in familial adenomatous polyposis patients with intact colons, ileorectal anastomosis surgery, or ileo-anal pullthrough (reservoir) surgery.

II. To measure markers of cell proliferation including colorectal mucosal levels of ornithine decarboxylase (ODC), polyamines, mucosal deoxyribonucleic acid (DNA) methylation, proliferative index (Ki67 antiproliferative cell nuclear antibody), apoptosis index, vascular density, mucosal prostaglandin, leukotriene levels, and activation of the nuclear factor kappa B (NFKB), and v-akt murine thymoma viral oncogene homolog 1 (Akt) survival pathways.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive curcumin orally (PO) twice daily (BID) for 12 months.

Arm II: Patients receive placebo PO BID for 12 months.

After completion of study treatment, patients are followed up at 4 months.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date November 30, 2016
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Patients with familial adenomatous polyposis who have undergone subtotal colectomy with ileorectal anastomosis, total colectomy with ileo-anal pull through (reservoir), and patients with intact colons with 5 or more adenomas in the rectum-sigmoid or reservoir

- Patients with familial adenomatous polyposis (FAP) and duodenal adenomatous polyposis without current lower tract adenomatous polyposis i.e. status/post (s/p) ileostomy

Exclusion Criteria:

- Female patients of childbearing age not on effective birth control

- Pregnant women

- White blood cell count (WBC) < 3500/ml

- Platelet count < 100,000/ml

- Blood urea nitrogen (BUN) > 25mg%

- Creatinine > 1.5mg%

- Patients unable to stop non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, curcumin, tumeric, calcium, vitamin D, green tea, or polyphenol E supplements for the duration of the trial

- Malignancy other than nonmelanoma skin cancer

- Active bacterial infection

- Patients with symptoms of active gastroesophageal reflux disease (GERD) (symptomatic despite medication or current erosive esophagitis on endoscopy)

- Patients with a history of peptic ulcer disease

- Patients on warfarin or plavix

Study Design


Intervention

Drug:
Curcumin
Given PO
Other:
Laboratory Biomarker Analysis
Correlative studies
Placebo
Given PO

Locations

Country Name City State
Puerto Rico University of Puerto Rico San Juan
United States Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Mucosal DNA Methylation Levels. Baseline to up to 12 months
Other Change in Mucosal Leukotriene Levels. Baseline to up to 12 months.
Other Change in Mucosal Prostaglandin Levels. Baseline to up to 12 months.
Other Number of Patients Failing Study. Patients withdrawn from study due to increasing polyp burden and/or advancing histology. Up to 16 months.
Other Change in Vascular Density Baseline up to 12 months
Other Activation of NFKB (Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells) Pathway Baseline to 12 months
Other Change in Akt Phosphorylation Levels Baseline up to 12 months
Primary Polyp Number Average number of polyps in the placebo arm at the end of the study is compared to the average in the curcumin arm Up to 12 months
Secondary Mean Polyp Size in mm Mean size of the 5 largest polyps Up to 12 months
Secondary Number of Participants With a Decrease in Polyp Burden at 12 Months The polyp burden as evaluated by video tape review. Polyp burden at 12 months compared to time 0 for each participant and counting participants with decrease in polyp burden at 12 months. 12 months
Secondary Number of Participants With Grade >=2 Adverse Events Events were graded as follows:
Grade 0= no adverse event or within normal limits; Grade 1= mild adverse event (causing no limitations of usual activity); Grade 2= moderate adverse event (causing some limitation of activity); Grade 3= severe adverse event (severe and undesirable; causing inability to carry out usual activities; Grade 4= life threatening or disabling adverse event; Grade 5= fatal adverse event.
Up to 12 months
Secondary Medication Compliance Medication compliance of the participant= number of capsules taken divided by the number of capsules prescribed as determined by pill count and described as a percentage per participant. Then the compliance of each participant in the assigned group (curcumin or placebo) was averaged together to obtain the medication compliance rate of that group. Up to 12 months
Secondary Change in Ornithine Decarboxylase (ODC) Activity Levels Change in ODC mean activity levels (expressed as nmol of activity/mg of mucosal tissue/hr) at 8 months compared to baseline (time 0) Baseline and 8 months
Secondary Change in Total Polyamines Levels Polyamine mean level changes (expressed as pg/mg protein) at month 8-baseline Baseline and 8 months
Secondary Change in Micro RNA 124-U6 (miR124-U6) Change in MicroRNA mean activity level at 8 months compared to baseline (time 0) Baseline and 8 months
Secondary Change in Spermidine/Spermine N-1 Acetyl Transferase (SSAT) Change in SSAT mean activity level at 8 months compared to baseline (time 0) Baseline and 8 months
Secondary Change in Spermine Oxidase (SMOX) Change in SMOX mean activity level at 8 months compared to baseline (time 0) Baseline and 8months
Secondary Change in Ki-67 Anti-proliferative Cell Nuclear Antibody Index Levels Change in cellular proliferation rate was measured by assessment of Ki-67 anti-proliferative cell nuclear antibody index levels at 8 months Baseline up to 8 months
Secondary Change in Apoptosis Index Levels Change in apoptosis index levels at 8 months by assessing cleaved Caspase-3 measurement 8 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05630794 - Testing ONC201 to Prevent Colorectal Cancer Phase 1
Completed NCT02961374 - Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer Phase 2
Completed NCT01483144 - Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Phase 3
Recruiting NCT03471403 - Cold Snare Polypectomy for Duodenal Adenomas in Familial Adenomatous Polyposis
Not yet recruiting NCT04531930 - Colorectal Adenoma Canceration in FAP
Recruiting NCT04678011 - A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy
Recruiting NCT04677998 - A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis
Completed NCT00927485 - Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP) N/A
Recruiting NCT00253812 - Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy N/A
Withdrawn NCT00248053 - Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients Phase 2
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Completed NCT04674228 - Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01
Completed NCT01656746 - Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease N/A
Completed NCT00808743 - Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Phase 2/Phase 3
Active, not recruiting NCT03847636 - CryoBalloon Ablation for Treatment of Duodenal Adenomas N/A
Not yet recruiting NCT05112822 - Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP) Phase 1
Recruiting NCT02656134 - Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP) N/A
Withdrawn NCT01245816 - A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) Phase 3
Recruiting NCT04709445 - Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses N/A
Enrolling by invitation NCT05402891 - The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis Phase 2